Multi-epitope chimeric antigen used as a serological marker to estimate Plasmodium falciparum transmission intensity in the border area of China-Myanmar.

The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet (2013) 6.70

Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A (2005) 6.39

Relationship between altitude and intensity of malaria transmission in the Usambara Mountains, Tanzania. J Med Entomol (2003) 3.98

From malaria control to eradication: The WHO perspective. Trop Med Int Health (2009) 3.85

Serology: a robust indicator of malaria transmission intensity? Trends Parasitol (2007) 3.63

Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51

Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol (1992) 3.12

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun (2002) 3.08

Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J (2008) 3.02

Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS One (2009) 2.94

A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90

New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis (2012) 2.52

Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J (2010) 2.47

Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog (2010) 2.30

Maximum likelihood for parasitologists. Parasitol Today (1994) 2.10

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun (2004) 2.02

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine (2005) 1.89

Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis (2010) 1.79

Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J (2008) 1.76

Changing malaria transmission and implications in China towards National Malaria Elimination Programme between 2010 and 2012. PLoS One (2013) 1.72

Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68

Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. Clin Vaccine Immunol (2006) 1.55

Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun (2003) 1.44

[Malaria situation in the People's Republic of China in 2011]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2012) 1.36

Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis (2008) 1.28

Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia. Malar J (2012) 1.27

Geographical patterns of allelic diversity in the Plasmodium falciparum malaria-vaccine candidate, merozoite surface protein-2. Ann Trop Med Parasitol (2001) 1.26

Development of a new platform for neglected tropical disease surveillance. Int J Parasitol (2012) 1.23

Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation. J Mol Biol (2006) 1.16

Widespread reactivity of human sera with a variant repeat of the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg (1990) 1.14

Antibody responses to several malaria pre-erythrocytic antigens as a marker of malaria exposure among travelers. Am J Trop Med Hyg (2006) 1.13

Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. Proc Natl Acad Sci U S A (2015) 1.13

Premunition against Plasmodium falciparum in a malaria hyperendemic village in Myanmar. Trans R Soc Trop Med Hyg (2001) 1.11

Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlands. BMC Infect Dis (2012) 1.07

Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. Malar J (2010) 1.07

Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans. PLoS One (2011) 1.01

Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int J Parasitol (2012) 0.96

Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax. PLoS One (2011) 0.93

A Cost-Effectiveness Analysis of Plasmodium falciparum Malaria Elimination in Hainan Province, 2002-2012. Am J Trop Med Hyg (2015) 0.91

Standardization and validation of a cytometric bead assay to assess antibodies to multiple Plasmodium falciparum recombinant antigens. Malar J (2012) 0.90

Assessment of exposure to Plasmodium falciparum transmission in a low endemicity area by using multiplex fluorescent microsphere-based serological assays. Parasit Vectors (2011) 0.90

Poverty and malaria in the Yunnan province, China. Infect Dis Poverty (2014) 0.89

Plasma concentration of malaria parasite-derived macrophage migration inhibitory factor in uncomplicated malaria patients correlates with parasitemia and disease severity. Clin Vaccine Immunol (2010) 0.83

Shrinking the malaria map in China: measuring the progress of the National Malaria Elimination Programme. Infect Dis Poverty (2016) 0.83

Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling. Vaccine (2007) 0.82

Effects of vector fusion peptides on the conformation and immune reactivity of epitope-shuffled, recombinant multi-epitope antigens. Protein Pept Lett (2011) 0.79

[Survey on Malaria Epidemics in China-Myanmar Border Area]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2015) 0.78

Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria. Vaccine (2004) 0.77